Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the first 60 days post CAR T dosing, and also through the collection of adverse events (AEs) and

Trial Details

NCT ID

NCT05887167

Phase

PHASE1

Sponsor

Joshua Sasine, MD, PhD

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

• autologous hematopoietic stem cells added to planned CAR T

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

• Age 18 - 85 years.
• Histologically proven hematological malignancy according to the World Health Organization 2016 classification criteria for which a commercially ava…
• Relapsed or refractory disease, defined by the following:
• Disease progression after last regimen, or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →